Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia

被引:47
作者
Meyers, CD [1 ]
Carr, MC [1 ]
Park, S [1 ]
Brunzell, JD [1 ]
机构
[1] Univ Washington, Sch Med, Seattle, WA USA
关键词
D O I
10.7326/0003-4819-139-12-200312160-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Nicotinic acid is an effective treatment for dyslipidemia, but the content of over-the-counter niacin is not federally regulated. As a result, patients may use preparations of over-the-counter niacin that do not contain free nicotinic acid. Objective: To characterize the types, costs, and free nicotinic acid content of over-the-counter niacin preparations and to review literature on the use of over-the-counter niacin for dyslipidemia. Data Sources: Commonly used over-the-counter niacin preparations (500-mg tablets or capsules) from the 3 categories of immediate-release, sustained-release, and no-flush were purchased at health food stores and pharmacies and from Internet-based vitamin companies. Pertinent literature on the use of over-the-counter niacin was obtained by. searching PubMed. Measurements: For each preparation studied, the monthly cost of therapy (at 2000 mg/d) and the free nicotinic acid content (quantified by high-performance liquid chromatography) were reported. Data Synthesis: On average, immediate-release niacin preparations cost $7.10 per month, sustained-release preparations cost $9.75 per month, and no-flush preparations cost $21.70 per month. The average content of free nicotinic acid was 520.4 mg for immediate-release niacin, 502.6 mg for sustained-release niacin, and 0 for no-flush niacin. Conclusions: No-flush preparations of over-the-counter niacin contain no free nicotinic acid and should not be used to treat dyslipidemia. Over-the-counter sustained-release niacin contains free nicotinic acid, but some brands are hepatotoxic. Immediate-release niacin contains free nicotinic acid and is the least expensive form of over-the-counter niacin.
引用
收藏
页码:996 / 1002
页数:7
相关论文
共 48 条
[1]  
ABOUELENEIN AM, 1983, NUTR REP INT, V28, P899
[2]  
AGUSTI R, 1978, REV INVEST CLIN, V30, P327
[3]   EFFECT OF A MODIFIED, WELL-TOLERATED NIACIN REGIMEN ON SERUM TOTAL CHOLESTEROL, HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND THE CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN RATIO [J].
ALDERMAN, JD ;
PASTERNAK, RC ;
SACKS, FM ;
SMITH, HS ;
MONRAD, ES ;
GROSSMAN, W .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 64 (12) :725-729
[4]   INFLUENCE OF NICOTINIC ACID ON SERUM CHOLESTEROL IN MAN [J].
ALTSCHUL, R ;
HOFFER, A ;
STEPHEN, JD .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1955, 54 (02) :558-559
[5]  
Altschul R, 1964, NIACIN VASCULAR DISO
[6]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[7]   Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia [J].
Aronov, DM ;
Keenan, JM ;
Akhmedzhanov, NM ;
Perova, NV ;
Oganov, RY ;
Kiseleva, NY .
ARCHIVES OF FAMILY MEDICINE, 1996, 5 (10) :567-575
[8]   Progression of coronary artery disease predicts clinical coronary events - Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study [J].
Azen, SP ;
Mack, WJ ;
CashinHemphill, L ;
LaBree, L ;
Shircore, AM ;
Selzer, RH ;
Blankenhorn, DH ;
Hodis, HN .
CIRCULATION, 1996, 93 (01) :34-41
[9]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[10]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298